This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

SHAREHOLDER ALERT: Investors With More Than $150,000 In Losses From Investments In Achillion Pharmaceuticals, Inc. Are Encouraged To Contact Wolf Haldenstein Before The December 9, 2013 Lead Plaintiff Deadline

On October 23, 2013, Wolf Haldenstein Adler Freeman & Herz LLP filed a class action lawsuit in the United States District Court on behalf of all persons who purchased or otherwise acquired common stock of Achillion Pharmaceuticals, Inc. (“Achillion” or the “Company”) [NASDAQ GS: ACHN] between August 8, 2012 and September 30, 2013, inclusive (the “Class Period”), against the Company and certain of the Company’s officers, alleging securities fraud pursuant to the Securities Exchange Act of 1934.

The litigation is styled Jiang v. Achillion Pharmaceuticals, Inc. A copy of the Complaint can be viewed on the Wolf Haldenstein website at www.whafh.com.

The Complaint alleges that during the Class Period, Achillion engaged in a fraudulent scheme to artificially inflate the Company’s stock price by disseminating false and misleading statements concerning its clinical trials of the drug sovaprevir. The Company falsely represented that sovaprevir, one of the protease inhibitor compounds intended as a treatment for the hepatitis C virus, was well-tolerated and had a low potential for drug-drug interactions. Indeed, Achillion touted the results of its clinical tests even though, in July 2013, the United States Food and Drug Administration (“FDA”) placed a clinical hold on sovaprevir.

Despite the Company’s repeated assurances, on September 27, 2013, Achillion announced that the FDA ultimately concluded that the removal of the clinical hold was not warranted. On this news, shares of Achillion fell 59.53% on intraday trading, to $2.94 per share on September 30, 2013.

If you purchased ACHN common stock during the Class Period, you may request that the Court appoint you as lead plaintiff by December 9, 2013. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.

Wolf Haldenstein has represented individual and institutional investors for many years, serving as lead counsel in numerous cases in United States federal and state courts. If you wish to discuss this action or have any questions, please contact Wolf Haldenstein Adler Freeman & Herz LLP at 270 Madison Avenue, New York, New York 10016, by telephone at (800) 575-0735 (Gregory M. Nespole, Esq.), via e-mail at classmember@whafh.com, or visit our website at www.whafh.com. All e-mail correspondence should make reference to “Achillion”.



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,161.12 +29.15 0.17%
S&P 500 2,004.93 +5.95 0.30%
NASDAQ 4,569.3640 +16.6050 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs